Company profile
GlobeStar Therapeutics Corporation
OTC: GSTC · Healthcare · Biotechnology
#1158 of 1,418 Healthcare companies by revenuebottom-quartile growth
EA Score
——FH —DQ 19GM —SS 44
v0.1 · 25/100 weight · pillars only
↑ listing tenure, growth stability · ↓ operating margin, net margin
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$1.9M
Employees
—
as of 2026-08-28
Market cap
$124.1k
as of 2026-08-28
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$77$772020
Net income-$1.9M-$1.9M2023
Operating income-$1.9M-$1.9M2023
Total assets$9.9k$9.9k2022
Liabilities$1.4M$1.4M2023
Equity-$1.4M-$1.4M2023
Revenue trend
FY2013 – FY2020 · USD
FY13
FY14
FY18
FY18
FY19
FY20
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is GlobeStar Therapeutics Corporation’s revenue?
GlobeStar Therapeutics Corporation booked $77 in FY2020 revenue, contracting 82% year over year — slower than 88% of Healthcare companies we track, at a -2531492.2% net margin.
Peers · Healthcare
Cannonau Corp.——Ludwig Enterprises, Inc.12DItonis, Inc.25DVMS Rehab Systems, Inc.——Goldenwell Biotech, Inc.16DRevolution Medicines, Inc.52DKey facts
CEOJames C. Katzaroff
SectorHealthcare
IndustryBiotechnology
HeadquartersRichland, WA
ExchangeOTC: GSTC
Employees—
IPO date2011-09-26
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.